Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

Abstract

Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received induction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimen was melphalan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4 subsequently relapsed. After a median follow-up of 31 months, 6 patients (49%) survived long term. Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT.

• Authors: Stefan O Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos Bueso-Ramos, Borje S Andersson, Chitra M Hosing, Srdan Verstovsek, Richard E Champlin, Uday Popat
• Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (Biol Blood Marrow Transplant) Vol. 16 Issue 4 Pg. 555-9 (Apr 2010) ISSN: 1523-6536 [Electronic] United States
• PMID: 20005966 (Publication Type: Journal Article)
• Copyright: Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Chemical References

• Melphalan

Topics

• Aged
• Cell Transformation, Neoplastic
• Disease-Free Survival
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia (pathology, therapy)
• Male
• Melphalan (administration & dosage, therapeutic use)
• Middle Aged
• Primary Myelofibrosis (pathology, therapy)
• Prognosis
• Transplantation Conditioning
• Treatment Outcome